Prostate cancer (PCa) and its treatments, most notably androgen-deprivation therapy (ADT), are associated with accelerated bone loss and increased risk of osteoporosis and fractures. Existing primary studies report heterogeneous estimates of bone disease burden in men with PCa, and comprehensive pooled prevalence figures have been limited.
This review addresses the gap by systematically collating available prevalence data for osteoporosis and low bone mass (osteopenia) among adult men with PCa across disease stages and by exploring study-level factors that may influence prevalence estimates.
To systematically review and meta-analyze the prevalence of osteoporosis and low bone mass in adult men with prostate cancer and to examine study-level moderators—such as ADT category and duration, BMD ascertainment methods, outcome definitions, geographic region, and study design—that could affect pooled prevalence estimates.
A comprehensive literature search was performed in PubMed, Scopus, Web of Science, Embase, CINAHL, and ProQuest for publications from January 1994 through October 2025. Eligible studies were population- or institution-based cross-sectional and cohort studies reporting the prevalence of osteoporosis or low bone mass among adult men with PCa.
Primary disease-state classifications used for pooled analyses were based on bone mineral density (BMD) T-score thresholds: osteoporosis as T-score ≤ -2.5 and low bone mass as T-score > -2.5 to < -1.0. Study-specific definitions and BMD ascertainment methods were extracted and used in subgroup analyses when available.
Risk of bias was assessed independently with the Joanna Briggs Institute checklist. Pooled prevalence estimates were derived using random-effects meta-analysis, heterogeneity quantified with the I2 statistic, and heterogeneity sources explored via subgroup, meta-regression, and sensitivity analyses.
Fifty-two studies encompassing 91,913 men with prostate cancer met inclusion criteria. All 52 studies contributed data to the osteoporosis analysis (7,042 reported osteoporosis cases), while 42 studies contributed to the low bone mass analysis.
Pooled prevalence estimates from random-effects models were:
Prevalence varied across subgroups defined by BMD ascertainment method, outcome definition, ADT category, geographic region, and study design. The authors note that many of these subgroup comparisons are exploratory because several subgroups contained only one or two studies. Methodological rather than clinical factors accounted for the largest differences between subgroup estimates.
Meta-regression examined publication year and ADT duration as potential moderators. Neither publication year nor ADT duration demonstrated a statistically significant association with overall prevalence. However, ADT duration was reported for only a subset of studies (24 studies for osteoporosis and 20 for low bone mass), and residual heterogeneity after covariate adjustment remained above 92%, so absence of a detected association does not rule out a real relationship.
Sensitivity analyses were performed and produced results similar to the main pooled estimates, supporting the robustness of the central prevalence findings despite high between-study variability.
This systematic review and meta-analysis indicates that osteoporosis and low bone mass are commonly reported among men with prostate cancer, with pooled prevalences of 22.0% and 41.7%, respectively. However, these estimates are constrained by very high heterogeneity across studies, largely driven by differences in densitometric methods, diagnostic definitions, and study methodologies.
Importantly, this review was limited to prevalence measures. It did not assess downstream clinical outcomes such as fracture incidence, nor did it evaluate the effectiveness of screening strategies or therapeutic interventions. Therefore, the analysis cannot establish whether any specific management approach reduces fracture risk in men with PCa.
The authors recommend future research in the form of standardized longitudinal studies using harmonized bone mineral density (BMD) assessment methods to better define incidence, temporal changes related to ADT and other treatments, and the impact of interventions on fractures and other clinically meaningful outcomes.
The publication includes declarations: ethics approval and consent to participate were not applicable; no materials from other sources required permission; no clinical trial number applies; consent for publication not applicable. The authors declared no competing interests.
The authors reported limited use of generative AI (Claude, Anthropic) during manuscript revision for language and clarity; all suggestions were critically reviewed and the authors retained responsibility for the manuscript content.
Note: The review provides pooled prevalence estimates and characterizes heterogeneity and methodological limitations; details beyond those reported (for example, fracture rates or intervention outcomes) were not assessed in this review and are therefore not reported here.